Prognostic Impact of Neopterin on Resumption of Walking After a Fracture of the Upper Neck of the… (NCT05233072) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Prognostic Impact of Neopterin on Resumption of Walking After a Fracture of the Upper Neck of the Femur in the Elderly
France150 participantsStarted 2022-05-16
Plain-language summary
Society faces a major challenge with the management of the health and socio-economic burden caused by acute physical stress in the older population (\>75 years). In particular, hip fracture (HF) represents a major health care preoccupation, affecting 1.6 M patients worldwide, resulting in a significant drop of life quality and autonomy. Nowadays, this trauma is still associated with a poor outcome of 20-30% one-year mortality in the elderly. This emphasizes the value of assessing biological factors that may predict clinical outcome after HF. The preliminary work pinpoints a central role of neopterin in loss of autonomy and death. Using HF as an acute stress model that accelerates the progressive course of aging, the aim is to validate neopterin as a predictive biomarker of pernicious clinical outcomes.
Who can participate
Age range
75 Years – 110 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
For both arms:
* age over 75
* affiliated to health insurance system
* written informed consent
For arm 'Fracture':
* patient with a fracture of the upper neck of the femur
* hospitalized in emergency in a 'UPOG' unit
For arm 'control':
* hospitalized patient without any acute clinical event
Exclusion Criteria:
For both arms:
* polytrauma
* pathological bone or prothesis fracture
* patient affiliated to 'Aide Médical de l'Etat - AME' insurance
* patient with immunosuppressant treatment (including corticotherapy over 5 mg/d)
* patient with active solid cancer or malignant haemopathy
* patient with auto-immune disease
* refusal to participate in research
For arm 'Fracture':
* patient under justice protection measure except tutorship and guardianship
For arm 'control':
* severe neurocognitive disorders (MMS \< 15)
* fracture of the upper neck of the femur in the last year
* patient under justice protection measure
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.